HeartX Success Story: iCardio.ai

Partner News | Published: Wednesday, April 16, 2025

---

About the Company

iCardio.ai is a Los Angeles-based company advancing machine learning and deep learning algorithms for ultrasound, focusing on transthoracic echocardiography. With a proprietary database of over 200 million ultrasound images, iCardio.ai enhances diagnostic accuracy and efficiency through artificial intelligence (AI). Their flagship product, EchoMeasure™, recently received U.S. Food and Drug Administration (FDA) 510(k) clearance, providing clinicians with an automated, comprehensive imaging workflow and preliminary reporting tool. Additionally, CardioVision™, an AI-based aortic stenosis detection tool, earned FDA Breakthrough Device Designation, addressing unmet needs in cardiac diagnostics. iCardio.ai has also formed key partnerships, including a multi-year collaboration with GE Healthcare to integrate its technology into GE ultrasound platforms, as well as agreements with UltraLinQ and SARC MedIQ, broadening the accessibility and utility of echocardiography AI.

The HeartX Experience

iCardio.ai joined the 2022 HeartX cohort, marking a key inflection point in the company’s growth. HeartX was their first accelerator program, offering critical early-stage funding and opening doors to vital relationships with healthcare providers and industry partners. During the program, they launched two significant clinical studies with Arkansas Heart Hospital and Conway Regional, which validated their algorithm for atherosclerosis detection. The resulting data helped secure Small Business Designation and strengthened their regulatory pathway by underpinning FDA submissions with robust clinical evidence. These studies supported the publication of abstracts at ACC and ASE, contributing to their FDA submission. Beyond the formal structure, the HeartX program fostered long-term relationships with MedAxiom, HealthTech Arkansas and clinical partners—connections that have continued to support the company’s progress. The trust, professional guidance, and early financial backing provided through HeartX were pivotal in accelerating iCardio.ai’s trajectory.

Participation in HeartX also paved the way for future opportunities, leading to their acceptance into the Cedars-Sinai Accelerator and Techstars Healthcare Accelerator. Following their HeartX experience, iCardio.ai’s network and credibility expanded significantly, culminating in partnerships with major healthcare organizations like Abbott, GE Healthcare, UltraLinQ and SARC MedIQ. Their ongoing collaborations continue to support product development and market expansion.

Over the next two years, iCardio.ai aims to broaden its AI portfolio. Plans include enhancing intracardiac echocardiography capabilities—specifically through a relationship with Abbott—and launching EchoGPT, an AI-powered tool capable of autonomously generating complete echocardiography reports. These innovations will further streamline workflows, improve diagnostic precision, and reinforce the company’s position as a leader in cardiac AI.

Testimonials

“HeartX was the first serious accelerator to take a chance on us. The experience, connections, and funding we received have been invaluable to our growth. It truly set the foundation for where we are today.” Joseph Sokol, CEO, iCardio.ai.

“Echocardiography is an essential tool for cardiologists in diagnosing and managing a wide range of cardiac conditions, including valvular heart disease, heart failure and coronary artery disease. The AI models developed by iCardio.ai have meaningfully advanced our ability to detect conditions like severe aortic stenosis with greater accuracy and consistency. This technology enables earlier diagnosis, empowers clinicians in making more confident decisions, and ultimately improves patient outcomes. By leveraging AI, we can enhance both the quality and efficiency of cardiac care.” Mahesh Bavineni, MD, MBA, Principal Investigator, Arkansas Heart Hospital.

« Back